Aquestive Therapeutics (AQST) Leases: 2019-2025
Historic Leases for Aquestive Therapeutics (AQST) over the last 6 years, with Sep 2025 value amounting to $4.8 million.
- Aquestive Therapeutics' Leases fell 10.19% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year decrease of 10.19%. This contributed to the annual value of $5.2 million for FY2024, which is 6.75% down from last year.
- As of Q3 2025, Aquestive Therapeutics' Leases stood at $4.8 million, which was down 2.89% from $4.9 million recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' Leases registered a high of $5.9 million during Q1 2023, and its lowest value of $2.1 million during Q3 2022.
- For the 3-year period, Aquestive Therapeutics' Leases averaged around $5.4 million, with its median value being $5.4 million (2024).
- Its Leases has fluctuated over the past 5 years, first declined by 28.21% in 2022, then surged by 170.73% in 2023.
- Over the past 5 years, Aquestive Therapeutics' Leases (Quarterly) stood at $2.7 million in 2021, then spiked by 91.23% to $5.2 million in 2022, then increased by 6.64% to $5.6 million in 2023, then decreased by 6.75% to $5.2 million in 2024, then declined by 10.19% to $4.8 million in 2025.
- Its Leases was $4.8 million in Q3 2025, compared to $4.9 million in Q2 2025 and $5.0 million in Q1 2025.